Nasdaq
$2.86▼ 1.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $25.2MShares out 8.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.29Pre-market26.09.29 19:574Ownership#●●●
111, Inc.
Insider Chen Yang Luke filed a Form 4 statement on September 29, 2026, reporting changes in beneficial ownership of securities for 111, Inc. as of September 28, 2026.…more
$2.86-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28Pre-market26.09.28 19:336-KKey event
111, Inc.
111, Inc. has established a special committee consisting of three independent directors to evaluate the non-binding acquisition proposal received on September 16, 2026, and other potential strategic alternatives. No decisions have been made regarding the proposal, and there is no assurance that any definitive agreement will be reached or consummated.…more
$2.86-1.38%vs prev closeView filingShare - 9.24Pre-market26.09.24 19:104Ownership
111, Inc.
Insider Chen Yang Luke of 111, Inc. filed a Form 4 on September 24, 2026, reporting a change in beneficial ownership of securities as of September 23, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$2.86-1.38%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.28Pre-market26.09.28 17:49#●●●
111, Inc. Forms Special Committee to Review Strategic Alternatives
111, Inc. has established a special committee of three independent directors to evaluate a recent acquisition proposal and other strategic alternatives. The company cautioned that no final decisions have been made regarding these matters.…more
$2.86-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.17Pre-market26.09.17 21:14
●●●●●●●● ●●●●● ●●●●●●
111 Inc. received an unsolicited buyout proposal from its co-founders at $4.52 per ADS, though the company reported declining revenue and widening losses for the second quarter. Investors should remain cautious given the poor financial performance and the non-binding nature of the acquisition offer.…more
$2.86-1.38%vs prev closeShareBenzinga - 9.17Pre-market26.09.17 20:11
●●●●●●●● ●●●●● ●●●●●●
Several companies including 111, Innate Pharma, and Upexi are scheduled to report their quarterly earnings. Investors should note that Innate Pharma and Upexi are projected to report quarterly losses.…more
$2.86-1.38%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report